Pioneering MedTech company secure commitments of over $21 million for its transformative cardiac bypass technology

Globally recognized entrepreneur and medical device developer Manny Villafaña PhD Sc. secures additional financing to accelerate his latest heart bypass surgery solution venture.

Medical 21, a MedTech company aiming to transform heart bypass surgery with a revolutionary artificial graft, says it has successfully closed more than $21 million in commitments recently as it spearheads its recently launched $40 million Regulation A+ investment offering that's open to the public as well as accredited investors.

Medical 21 was founded by Manny Villafaña, PhD Sc., whose previous heart innovations have positively impacted 15 million people, while his seven earlier MedTech ventures included three exits totalling $57.4 billion in shareholder value through acquisitions by Abbott, Boston Scientific, and Medtronic.

A Medical 21 artificial graft aims to prevent the need to harvest blood vessels from the leg, opening it up to millions more people who couldn’t have these treatments because of things like diabetes, infection or amputees.

Such achievements have earned Dr Villafaña a reputation as the "Living Legend of Medicine." He expects Medical 21 to be his greatest: "With our experience and successes, we are ready to pursue the "holy grail" of cardiac surgery and its great market potential: a small diameter graft for bypass surgery that has evaded manufacturers and health institutions for 50 years."

Medical 21's breakthrough is set to drastically improve the recovery of heart bypass patients and assist cardiac surgeons by reducing time in the operating room.

Medical 21 CEO and Founder, Manny Villafaña.

Nanotechnology has been incorporated into many different MedTech solutions and continues to hold tremendous potential for enhancing the treatment of heart disease.

Nanotechnology has also been reported to improve coronary Stent applications using nano-fibrous scaffolds for application in artery bypass grafting by facilitating secular implementation and remodelling of the graft matrix.

Medical 21's recent $21 million in commitments will accelerate the development of Medical 21's artificial graft in preparation for a US Food & Drug Administration Early Feasibility Study (EFS), likely to go live before the end of 2022.

Dr Villafaña is the Founder of Cardiac Pacemakers Inc./Guidant (acquired by Boston Scientific), the Founder of St. Jude Medical (acquired by Abbott), and the Founder of ATS Medical (acquired by Medtronic) for more than $50 billion in total shareholder value. He added:

"Medical 21 is the company I'm most excited about because of its enormous potential to improve conditions for the millions of coronary artery heart bypass surgery patients. It could be the biggest ever cardiac surgery innovation because it avoids the painful and invasive 'harvesting' of the patient's blood vessels to supply the heart bypass grafts."

Medical 21 will also continue to seek further capital through its current $40 million Regulation A+ equity crowdfunding offering, with strategic guidance from Medical Funding Professionals (MFP) and its partner Life Science Intelligence (LSI). A copy of the Regulation A+ offering circular and how to invest can be found on Medical 21's website here. Prospective investors in the Regulation A+ offering should read the offering circular before investing.

Medical 21’s artificial graft development is being accelerated by its recent $21 million in commitments.

Dr Villafaña added: "We see crowdfunding as the 21st century way to fund a company and bring such a life-changing solution to market. Scott Pantel of LSI and Stephen Brock of MFP lead our efforts and continue to do an outstanding job, not only for the investment offering but also building exposure to a broader investor network."

MFP CEO Stephen Brock said: "We all know about the devastating impacts of cardiovascular disease and how intrusive and painful current bypass procedures can be. Medical 21's technology will potentially revolutionize how these surgeries are conducted and eradicate suffering."

Scott Pantel, CEO of LSI - and MFP strategic partner – said: "This recent investment is a huge vote of confidence in Medical 21 and demonstrates substantial interest from investors to get involved in exciting MedTech companies. Medical 21 is going after a big problem, and investors want to get involved so they can do good; they are following someone with an enviable and proven track record in delivering innovation for patients in this field.

"We were honoured to have Dr Villafaña speak in London a month ago at our LSI Europe '22 Emerging MedTech Summit."

To learn more about Medical 21, you can register now for its upcoming webinar, hosted by founder and legendary entrepreneur Manny Villafaña.

Secure your spot at Medical 21's webinar event and find out how you can have your investment stake or interest in this MedTech company taking place on November 14th at 3 PM EST by registering here.